Aimin Jiang

1.3k total citations · 3 hit papers
52 papers, 717 citations indexed

About

Aimin Jiang is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Aimin Jiang has authored 52 papers receiving a total of 717 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 22 papers in Molecular Biology and 13 papers in Epidemiology. Recurrent topics in Aimin Jiang's work include Cancer Immunotherapy and Biomarkers (13 papers), Ferroptosis and cancer prognosis (7 papers) and Cancer-related molecular mechanisms research (7 papers). Aimin Jiang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (13 papers), Ferroptosis and cancer prognosis (7 papers) and Cancer-related molecular mechanisms research (7 papers). Aimin Jiang collaborates with scholars based in China, Hong Kong and United States. Aimin Jiang's co-authors include Xiaoqiang Zheng, Peng Luo, Na Liu, Anqi Lin, Quan Cheng, Tao Tian, Jian Zhang, Yu Yao, Xiao Fu and Zhiping Ruan and has published in prestigious journals such as SHILAP Revista de lepidopterología, ACS Nano and Scientific Reports.

In The Last Decade

Aimin Jiang

47 papers receiving 712 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database

2023 114 citations Anqi Lin, Aimin Jiang et al. profile →
iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response prediction

2025 57 citations Bicheng Ye, Jun Fan et al. iMeta profile →
Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review

2024 54 citations Aimin Jiang, Anqi Lin et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Aimin Jiang China	15	316	201	186	128	119	52	717
Xinji Zhang China	18	391 1.2×	144 0.7×	205 1.1×	188 1.5×	153 1.3×	52	890
Yuwen Zhou China	15	405 1.3×	213 1.1×	194 1.0×	103 0.8×	86 0.7×	53	868
Seyyed Mohammad Amin Kashani Iran	6	511 1.6×	214 1.1×	151 0.8×	273 2.1×	62 0.5×	8	1.0k
Michaëla Semeraro France	17	319 1.0×	224 1.1×	117 0.6×	276 2.2×	68 0.6×	34	989
Marija Mihajlović Serbia	10	319 1.0×	196 1.0×	66 0.4×	146 1.1×	88 0.7×	38	735
Muhammad Irfan Pakistan	17	290 0.9×	165 0.8×	159 0.9×	40 0.3×	210 1.8×	104	871
Monika Lamba Saini India	12	261 0.8×	269 1.3×	119 0.6×	40 0.3×	69 0.6×	32	668
Samantha M. Ruff United States	14	304 1.0×	217 1.1×	229 1.2×	70 0.5×	181 1.5×	88	970

Countries citing papers authored by Aimin Jiang

Since Specialization

Citations

This map shows the geographic impact of Aimin Jiang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aimin Jiang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aimin Jiang more than expected).

Fields of papers citing papers by Aimin Jiang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aimin Jiang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aimin Jiang. The network helps show where Aimin Jiang may publish in the future.

Co-authorship network of co-authors of Aimin Jiang

This figure shows the co-authorship network connecting the top 25 collaborators of Aimin Jiang. A scholar is included among the top collaborators of Aimin Jiang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aimin Jiang. Aimin Jiang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Zhanfeng, Aimin Jiang, Siqi Yan, et al.. (2025). Enhancing PD-1 blockade in NSCLC: Reprogramming tumor immune microenvironment with albumin-bound statins targeting lipid rafts and mitochondrial respiration. Bioactive Materials. 49. 140–153. 3 indexed citations

Li, Zhengrui, Aimin Jiang, Jinghong Chen, et al.. (2025). Immunotherapy-induced cholestasis in cancer: insights from the two real-world pharmacovigilance databases of FAERS and VigiBase. International Journal of Surgery. 111(8). 5105–5121. 2 indexed citations

Ye, Bicheng, Jun Fan, Lei Xue, et al.. (2025). iMLGAM: Integrated Machine Learning and Genetic Algorithm‐driven Multiomics analysis for pan‐cancer immunotherapy response prediction. iMeta. 4(2). e70011–e70011. 57 indexed citations breakdown →

Jiang, Aimin, et al.. (2025). A Novel Age-Based Nomogram as the Best Predictor for Long-Term Overall Survival in Head and Neck Mucosa-Associated Lymphoid Tissue Lymphoma. Cancer Control. 32. 2935739709–2935739709.

Jiang, Aimin, Hong Lu, Rui Zhao, Jupeng Yuan, & Dawei Chen. (2025). The impact of pre-existing interstitial lung disease on radiation and checkpoint inhibitor pneumonitis in lung cancer patients: a systematic review and meta-analysis. Therapeutic Advances in Medical Oncology. 17. 22783360–22783360. 1 indexed citations

Lin, Anqi, Zhengrui Li, Aimin Jiang, et al.. (2025). Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence. Biomarker Research. 13(1). 50–50. 14 indexed citations

Yu, Haijun, Chunyan Zhang, Aimin Jiang, et al.. (2025). Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors. npj Biofilms and Microbiomes. 11(1). 180–180. 4 indexed citations

Li, Jinxin, Ying Liu, Yu Fang, et al.. (2025). Drug resistance in cancer: molecular mechanisms and emerging treatment strategies. Molecular Biomedicine. 6(1). 111–111.

Liu, Na, Xiaoqiang Zheng, Jin Yan, et al.. (2024). Reversing MET‐Mediated Resistance in Oncogene‐Driven NSCLC by MET‐Activated Wnt Condensative Prodrug. Advanced Science. 11(30). e2400603–e2400603. 5 indexed citations

10.

Jiang, Aimin, Jinxin Li, Ying Liu, et al.. (2024). Renal cancer: signaling pathways and advances in targeted therapies. SHILAP Revista de lepidopterología. 5(8). e676–e676. 9 indexed citations

11.

Ye, Bicheng, et al.. (2024). Navigating the immune landscape with plasma cells: A pan‐cancer signature for precision immunotherapy. BioFactors. 51(1). e2142–e2142. 28 indexed citations

12.

Jiang, Aimin, Zhengang Qiu, Anqi Lin, et al.. (2024). Novel perspectives on the link between obesity and cancer risk: from mechanisms to clinical implications. Frontiers of Medicine. 18(6). 945–968. 6 indexed citations

13.

Yan, Huiyu, Aimin Jiang, Yinong Huang, et al.. (2023). Exercise sensitizes PD-1/PD-L1 immunotherapy as a hypoxia modulator in the tumor microenvironment of melanoma. Frontiers in Immunology. 14. 1265914–1265914. 13 indexed citations

14.

Zheng, Haoran, Aimin Jiang, Na Liu, et al.. (2022). The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study. Cancer Management and Research. Volume 14. 2273–2287. 11 indexed citations

15.

Chen, Xue, Aimin Jiang, Rui Zhang, et al.. (2022). Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis. Frontiers in Cardiovascular Medicine. 9. 882167–882167. 22 indexed citations

16.

Jiang, Aimin, Haoran Zheng, Na Liu, et al.. (2021). Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis. Cancer Control. 28. 2895468629–2895468629. 5 indexed citations

17.

Jiang, Aimin, Na Liu, Rui Zhao, et al.. (2021). Construction and Validation of a Novel Nomogram to Predict the Overall Survival of Patients With Combined Small Cell Lung Cancer: A Surveillance, Epidemiology, and End Results Population-Based Study. Cancer Control. 28. 2895469276–2895469276. 7 indexed citations

18.

Fu, Xiao, Zhiyan Liu, Mengjie Liu, et al.. (2020). <p>PD-L1 Predicts Poor Prognosis in Surgically Resected Limited Stage Small-Cell Lung Cancer</p>. Cancer Management and Research. Volume 12. 10939–10948. 10 indexed citations

19.

Jiang, Aimin, Na Liu, Huan Gao, et al.. (2020). <p>Nosocomial Infections in Gastrointestinal Cancer Patients: Bacterial Profile, Antibiotic Resistance Pattern, and Prognostic Factors</p>. Cancer Management and Research. Volume 12. 4969–4979. 8 indexed citations

20.

Jiang, Aimin, Na Liu, Rui Zhao, et al.. (2020). Clinical outcomes and prognostic factors in bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae among patients with malignancy: a meta-analysis. Annals of Clinical Microbiology and Antimicrobials. 19(1). 53–53. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact